ADC Therapeutics S.A. (NYSE:ADCT) Q3 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q3 2025 Earnings Conference Call. At this time, lines are in listen-only mode.
Adc Therapeutics Sa (ADCT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 15,666,731 | $62,666,924 | 6.1% | |
| 2. | Point72 Asset Management Steve Cohen | 8,135,651 | $32,542,604 | +5% | 0.05% |
| 3. | Prosight Capital Lawrence Hawkins | 7,472,303 | $29,889,212 | -29% | 6.97% |
| 4. | OrbiMed Advisors Samuel Isaly | 5,907,351 | $23,629,404 | 0.56% | |
| 5. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,266,289 | $9,065,156 | 0.31% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.81 | 50,000 | $190,500.00 | 13,145,712 | 2024-12-11 | Filing | |
| $2.28 | 50,000 | $114,000.00 | 13,095,712 | 2024-12-11 | Filing | |
| $3.81 | 50,000 | $190,500.00 | 15,666,731 | 2024-12-11 | Filing | |
| $2.28 | 50,000 | $114,000.00 | 15,616,731 | 2024-12-11 | Filing | |
| $2.81 | 400,000 | $1,124,000.00 | 12,995,040 | 2024-07-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.07 | 25,352 | $52,478.64 | 15,566,731 | 2024-12-04 | Filing | |
| $2.89 | 6,995 | $20,215.55 | 53,005 | 2024-06-17 | Filing | |
| $2.89 | 6,995 | $20,215.55 | 79,502 | 2024-06-17 | Filing | |
| $2.89 | 1,193 | $3,447.77 | 182,644 | 2024-06-17 | Filing | |
| $2.89 | 1,437 | $4,152.93 | 106,627 | 2024-06-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,511,699 | $18,046,796 | 0% | |
| 2. | 3,669,067 | $14,676,268 | 0% | |
| 3. | 1,594,434 | $6,377,736 | 0% | |
| 4. | 1,390,175 | $5,560,700 | 0.27% | |
| 5. | 1,361,290 | $5,445,160 | 0% |
News See All
ADC Therapeutics (ADCT) Secures PIPE Financing, Price Target Adjusted
ADC Therapeutics S.A. (NYSE:ADCT) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 16, H.C.
Billionaire Steve Cohen's 10 Small-Cap Stock Picks with Huge Upside Potential
Known for speed, agility, and a high-risk, high-reward investment approach, Steve Cohen is one of the most successful hedge fund managers on Wall Street.
H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement
ADC Therapeutics (NYSE:ADCT) is one of the best long term penny stocks with huge upside potential. On October 16, H.C.
10 Best Long Term Penny Stocks with Huge Upside Potential
On October 2, Dan Veru, Palisade Capital Management senior partner and CIO, joined 'Power Lunch' on CNBC to discuss the opportunities available in small-cap stocks and talk about the start of the first...
ADC Therapeutics S.A. (ADCT) Eyes Billion Dollar Opportunity with ZYNLATA Indication Expansion
ADC Therapeutics S.A. (NYSE:ADCT) is one of the best performing penny stocks to buy now.
10 Best Performing Penny Stocks to Buy Now
Long-lagging small-cap and penny stocks are increasingly capturing the attention of value investors.
ADC Therapeutics S.A. (NYSE:ADCT) Q2 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics SA ADCT Q2 2025 Earnings Conference Call.
ADC Therapeutics SA (NYSE:ADCT) Q1 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to ADC Therapeutics' First Quarter 2025 Earnings Call.
ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Fourth Quarter Fiscal Year 2024 Earnings Conference Call. At this time, all lines are in listen-only mode.
Hedge Fund Resource Center Billionaire Hedge Funds
